Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 570-574

  Duval, Xavier ^a   Lamotte, Claire ^a   Race, Ester ^a   Descamps, Diane ^a   Damond, Florence ^a   Clavel, François ^a   Leport, Catherine ^a   Peytavin, Gilles ^a   Vilde, Jean Louis ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SALVAGE THERAPY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; RITONAVIR; RNA, VIRAL; SULFONAMIDES;

EID: 0036148608     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.570-574.2002     Document Type: Article

References (12)

1. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
2. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir
3. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
4. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
5. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
6. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy
7. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse transcription and amplification reaction
8. Analysis of HIV-cross resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
9. Pharmakokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
10. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, coadministration to healthy volunteers
11. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors
12. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies; a review